Last $33.70 USD
Change Today +0.06 / 0.18%
Volume 89.6K
ARTC On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 05/24/13 All times are local (Market data is delayed by at least 15 minutes).

arthrocare corp (ARTC) Snapshot

Open
$33.48
Previous Close
$33.64
Day High
$33.71
Day Low
$33.17
52 Week High
01/29/13 - $36.99
52 Week Low
05/25/12 - $25.41
Market Cap
950.3M
Average Volume 10 Days
133.6K
EPS TTM
$1.53
Shares Outstanding
28.2M
EX-Date
--
P/E TM
22.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for ARTHROCARE CORP (ARTC)

Related News

No related news articles were found.

arthrocare corp (ARTC) Related Businessweek News

No Related Businessweek News Found

arthrocare corp (ARTC) Details

ArthroCare Corporation, medical device company, engages in the development, manufacture, and marketing of surgical products based on its Coblation technology in the Americas and internationally. It offers sports medicine products, including ArthroWands that features Coblation based specialized disposable energy-based surgical wands for single patient use to treat shoulder, knee, hip, foot, ankle, elbow, and wrist injuries; and soft-tissue fixation products, such as knotless and traditional anchors for rotator cuff and labrum repairs in the shoulder, screws for ligament reconstruction in the knee, and arthroscopic suture passers, as well as reusable hand-held instruments, procedural kits, and accessories. The company also provides ear nose and throat products consisting of suction wands, channeling wands, and excision wands; carboxymethyl-cellulose based packing and tamponade products that are used in nosebleed or epistaxis, as well as in treatments in an emergency room setting or surgicenter; dissolvable Stammberger sinus dressing and sinu knits to control minor bleeding, facilitate epithelial healing, and preserve the spatial integrity of the sinus area; and epistaxis balloon tamponade products for the hospital emergency room environment to control severe nosebleeds. In addition, it offers SpineWand devices to treat soft tissue conditions in spine; Plasma Disc decompression SpineWands for treating contained herniated discs; Cavity SpineWand to reduce the size of malignant lesions in the vertebrae of patients suffering from spinal compression fractures; and WoundWand for wound debridement in acute and chronic wounds and wound cleansing by removal of necrotic tissue. The company sells its products to surgeons and specialized medical professionals through sales representatives, and independent sales agents and distributors. ArthroCare Corporation was founded in 1993 and is headquartered in Austin, Texas.

1,700 Employees
Last Reported Date: 02/14/13
Founded in 1993

arthrocare corp (ARTC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $564.8K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $370.2K
Senior Vice President of Global Markets & Sal...
Total Annual Compensation: $308.6K
Senior Vice President and General Manager of ...
Total Annual Compensation: $306.2K
Chief Technical Officer and Senior Vice Presi...
Total Annual Compensation: $285.1K
Compensation as of Fiscal Year 2012.

arthrocare corp (ARTC) Key Developments

ArthroCare Corporation Announces Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2013; Provides Earnings Guidance for the Full Year 3013

ArthroCare Corporation announced unaudited consolidated financial results for the first quarter ended March 31, 2013. Total revenue for the first quarter of 2013 was $92.3 million, compared to $92.9 million for the first quarter of 2012, a decrease of less than 1%. Income from operations for the first quarter of 2013 was $13.5 million compared to $17.4 million for the same period in 2012. Net income available to common stockholders was $10.3 million or $0.30 per basic and diluted share in the first quarter of 2013, compared to $12.1 million, or $0.36 per basic and diluted share in the first quarter of 2012. Income from continuing operations before income taxes was $14 million against $17.8 million a year ago. Non-GAAP adjusted income from operations was $17.4 million against $18.5 million a year ago. Cash flows provided by operating activities for the quarter ended March 31, 2013 was $19.5 million compared to cash used in operations of $55.5 million for the quarter ended March 31, 2012 which included the payment of $74 million required to settle the private securities class actions against the Company. Adjusted for this payment, cash flows provided by operating activities would have been $18.5 million in the first quarter of 2012. For full year 3013, the company expects overall revenue growth to be between 2% and 4.5%. Operating margin outlook for 2013 was to achieve an adjusted operating margin equivalent to 2011 operating margin, which was 18.4%. Normal effective tax rate would be approximately 27%.

ArthroCare Corporation, Q1 2013 Earnings Call, May 08, 2013

ArthroCare Corporation, Q1 2013 Earnings Call, May 08, 2013

ArthroCare Corporation to Report Q1, 2013 Results on May 07, 2013

ArthroCare Corporation announced that they will report Q1, 2013 results at 5:00 PM, Eastern Standard Time on May 07, 2013

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARTC:US $33.70 USD +0.06

ARTC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ICU Medical Inc $70.68 USD +1.80
Merit Medical Systems Inc $9.96 USD -0.01
Orthofix International NV $26.52 USD -0.34
Tornier NV $16.92 USD +0.02
Wright Medical Group Inc $23.91 USD +0.18
View Industry Companies
 

Industry Analysis

ARTC

Industry Average

Valuation ARTC Industry Range
Price/Earnings 28.3x
Price/Sales 2.6x
Price/Book 2.5x
Price/Cash Flow 19.5x
TEV/Sales 1.7x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARTHROCARE CORP, please visit www.arthrocare.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.